Drug intelligence / Profile preview

thymopentin

Development stage
Phase 3
Modality
Small Molecules, Peptides
Administration
Intravenous, Intramuscular, Subcutaneous
01

Overview

Thymopentin is a synthetic pentapeptide that mimics the active site of the naturally occurring thymic hormone thymopoietin. It acts as an immunomodulator by promoting the differentiation and maturation of thymic T cells and natural killer (NK) cells, enhancing T helper cell function, and regulating T cell subset proportions. Its mechanism involves increasing intracellular cyclic adenosine monophosphate levels and modulating immune responses. Clinically, it has been used in autoimmune diseases (such as rheumatoid arthritis), immunodeficiency disorders (including HIV infection), adjunctive cancer therapy (e.g., chronic lymphocytic leukemia, Sezary's syndrome), atopic dermatitis, hepatocellular carcinoma, and to restore immune competence in elderly surgical patients or those with immunosuppression due to chemotherapy or radiotherapy. Due to poor membrane permeability and rapid metabolism resulting in a short half-life (~30 seconds), repeated injections or intravenous infusions are required for therapeutic effect[1][2][3][4][5][6][7].

Brand names
ImmunoxTimunox
Other names
ThymopentineThymopentinumTimopentinaPentapeptide, ThymopoietinThymopoietin Pentapeptide
02

Targets

HLA-DR (Human leukocyte antigen DR)AChR (Acetylcholine receptor)

Beyond the preview

Go deeper on thymopentin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on thymopentin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call